Patents by Inventor Matthew Charles Weber

Matthew Charles Weber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONIST FUSION PROTEIN FOR CD40 AND OX40 AND USES THEREOF
    Publication number: 20250115673
    Abstract: Provided is a fusion protein comprising an agonist for CD40 and an agonist for OX40. Compositions comprising the fusion protein and methods of use are also provided.
    Type: Application
    Filed: May 23, 2024
    Publication date: April 10, 2025
    Inventors: Mark L. Tykocinski, Matthew Charles Weber
  • AGONIST FUSION PROTEIN FOR CD40 AND OX40 AND USES THEREOF
    Publication number: 20200239584
    Abstract: Provided is a fusion protein comprising an agonist for CD40 and an agonist for OX40. Compositions comprising the fusion protein and methods of use are also provided.
    Type: Application
    Filed: December 24, 2019
    Publication date: July 30, 2020
    Inventors: Mark L. Tykocinski, Matthew Charles Weber
  • Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
    Patent number: 10533054
    Abstract: Provided is a fusion protein comprising an agonist for CD40 and an agonist for OX40. Compositions comprising the fusion protein and methods of use are also provided.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: January 14, 2020
    Assignee: Thomas Jefferson University
    Inventors: Mark L. Tykocinski, Matthew Charles Weber
  • AGONIST FUSION PROTEIN FOR CD40 AND OX40 AND USES THEREOF
    Publication number: 20150368350
    Abstract: Members of the TNF ligand/TNF receptor superfamily play key roles in a large number of biological events. For instance, members of the TNF ligand/TNF receptor superfamily figure prominently in the complex interplay of positive and negative signals that regulate T cell activation, maintenance of T cell effector function, promotion of maturation of antigen-presenting cells, such as dendritic cells, and the T cell stimulation of APCs. TNF receptors are broadly classified in three groups Receptors in the first group contain a death domain in their cytoplasmic tails. Receptors in the second group contain a TRAF interaction motif in their cytoplasmic tails. The third group of TNF receptors do not contain functional intracellular signaling domains but can act as decoy receptors.
    Type: Application
    Filed: January 31, 2014
    Publication date: December 24, 2015
    Inventors: Mark L. Tykocinski, Matthew Charles Weber